2024 - A Holistic Approach to Parkinson’s Disease Endpoint Data Collection: Efficacy, Safety and Quality of Life

In this webinar, the expert speakers will comprehensively explore Parkinson’s disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life. The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.
The speakers will present compelling evidence underscoring the heightened sensitivity of digital measures in monitoring Parkinson’s disease progression compared to conventional clinical scales. Furthermore, they will dissect the efficacy and quality of life evaluations by leveraging clinical rating scales, patient-reported outcomes and the distinctive utility of the on/off dyskinesia diary.
They will also review the significance of imaging features in accurately characterizing Parkinson’s disease biologically, paving the way for biomarker-guided drug development. Neuroimaging reveals striatal dopaminergic neuronal loss and the structure, function and integrity of motor circuitry throughout the brain. These circuits represent crucial targets for assessing patient eligibility, safety and therapeutic efficacy in the development of disease-modifying therapies.
Delving into safety considerations, the speakers will explore the impact of autonomic dysfunction associated with Parkinson’s disease, and the role for high-quality blood pressure data and heart rate variability analysis to characterize this. In addition, they will review QT interval monitoring strategies and some practical insights into implementing cardiac safety monitoring in this unique population.
Register to attend this webinar to learn about the complexities of Parkinson’s disease endpoint data collection and obtain invaluable insights for improving patient outcomes and advancing therapeutic interventions.
Keywords: PD, HV QT, FiH QT, First-in-Human QT, QT Risk, QT assessment, EPQT, EKG trial, ECG trial, Electrocardiogram, Cardiac Risk, TQT Waiver, Parkinson's Disease, Neuroimaging, AI, Artificial Intelligence, Cardiac Safety, TQT, CNS,  QT, QTc, Blood Pressure, Biomarkers, Clinical Research